Intellipharmaceutics international inc. (IPCI)
Balance Sheet / TTM
Aug'18May'18Nov'17Nov'15Nov'14Feb'14Nov'13Nov'12Nov'11Nov'10
Assets
Current
Cash

57

1,360

1,897

1,755

4,233

5,604

760

497

4,817

789

Accounts receivable, net

263

445

689

478

1,011

3,090

1,475

2

3

1

Investment tax credits

771

726

636

458

324

242

179

301

349

1,184

Prepaid expenses, sundry and other assets

566

458

225

229

414

291

312

137

124

142

Inventory (Note 3)

250

185

115

-

-

-

-

-

-

-

Current Assets

1,909

3,177

3,563

2,921

5,984

9,228

2,728

939

5,295

2,117

Deferred offering costs (Note 6)

814

431

565

543

271

-

419

-

-

224

Property and equipment, net (Note 4)

2,909

3,059

3,267

1,759

1,618

1,225

1,231

1,535

951

925

Assets

5,633

6,668

7,396

5,224

7,875

10,454

4,379

2,474

6,247

3,267

Liabilities
Current
Accounts payable

5,857

2,931

2,060

3,027

668

573

810

512

554

612

Accrued liabilities

741

708

782

454

675

616

669

224

436

321

Employee costs payable

216

223

214

175

181

197

508

663

736

575

Capital lease obligations (Note 9)

-

-

-

20

21

28

43

51

43

13

Due to related parties (Note 7)

-

-

-

-

-

738

759

783

757

1,635

Convertible debenture (Note 5)

1,338

1,322

1,290

1,518

1,377

1,404

2,105

-

-

-

Deferred revenue (Note 3)

300

300

300

-

-

-

-

-

-

-

Current Liabilities

8,455

5,486

4,647

5,196

2,923

3,559

4,896

2,235

2,526

3,158

Capital lease obligations (Note 9)

-

-

-

15

42

-

-

46

95

-

Deferred revenue (Note 3)

2,137

2,212

2,362

150

-

-

-

-

107

8

Warrant liabilities (Note 14)

-

-

-

-

-

-

5,438

1,960

6,611

7

Liabilities

10,593

7,698

7,010

5,361

2,965

3,559

10,334

4,242

9,340

3,174

Shareholders' (deficiency)/equity
Unlimited common shares without par value (in Shares)

-

-

-

-

-

0

-

0

0

0

Unlimited preference shares (in Shares)

-

-

-

-

-

0

-

0

0

0

Capital stock (Note 6, 7 and 9) Authorized Unlimited common shares without par value Unlimited preference shares Issued and outstanding 4,353,678 common shares (November 30, 2017 - 3,470,451)

38,697

38,697

35,290

21,481

18,941

16,334

11,721

6,128

147

16

Additional paid-in capital

37,895

37,869

36,685

30,969

31,119

29,654

23,619

22,428

20,822

19,369

Accumulated other comprehensive income

284

284

284

284

284

284

284

-240

-115

-225

Accumulated deficit

-81,836

-77,882

-71,873

-52,872

-45,436

-39,378

-41,579

-30,084

-23,947

-19,067

Shareholders' (Deficiency)/Equity

-4,959

-1,030

386

-137

4,909

6,895

-5,955

-1,767

-3,093

92

Contingencies (Note 11)

0

0

0

0

0

0

0

0

0

0

Liabilities and Shareholders' (Deficiency)/Equity

5,633

6,668

7,396

5,224

7,875

10,454

4,379

2,474

6,247

3,267